The consortium will establish in vitro and in vivo models to evaluate new antiviral compounds active against SARS-CoV-2. The aim is to develop broad-spectrum antivirals that can be administered locally to the nose and/or lungs.
We will map local immune responses in the lungs of mice infected with RSV and compare the responses occurring after treatment using an oligonucleotide with capacity to inhibit RSV infection.